Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Chromosome 5q deletions (del[5q]) are common in high-risk (HR) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); however, the gene regulatory networks that sustain these aggressive diseases are unknown. Reduced miR-146a expression in del(5q) HR MDS/AML and miR-146a(-/-) hematopoietic stem/progenitor cells (HSPCs) results in TRAF6/NF-κB activation. Increased survival and proliferation of HSPCs from miR-146a(low) HR MDS/AML is sustained by a neighboring haploid gene, SQSTM1 (p62), expressed from the intact 5q allele. Overexpression of p62 from the intact allele occurs through NF-κB-dependent feedforward signaling mediated by miR-146a deficiency. p62 is necessary for TRAF6-mediated NF-κB signaling, as disrupting the p62-TRAF6 signaling complex results in cell-cycle arrest and apoptosis of MDS/AML cells. Thus, del(5q) HR MDS/AML employs an intrachromosomal gene network involving loss of miR-146a and haploid overexpression of p62 via NF-κB to sustain TRAF6/NF-κB signaling for cell survival and proliferation. Interfering with the p62-TRAF6 signaling complex represents a therapeutic option in miR-146a-deficient and aggressive del(5q) MDS/AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ToppGene Suite for gene list enrichment analysis and candidate gene prioritization
Chen, J., Bardes, E. E., Aronow, B. J., & Jegga, A. G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp427 · Cited by 2,952
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · cited 1×
“5q- syndrome, a clinical entity defined by an isolated del(5q) with a blast count of <5% confers a favorable prognosis and responsiveness to lenalidomide(Greenberg et al., 2012; List et al., 2006).”
Backgroundp62 at the crossroads of autophagy, apoptosis, and cancer
Moscat, J., & Diaz-Meco, M. T. (2009) · Cell · doi:10.1016/j.cell.2009.05.023 · Cited by 1,073
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Boldin, M. P., Taganov, K. D., Rao, D. S., Yang, L., Zhao, J. L., Kalwani, M., Garcia-Flores, Y., Luong, M., Devrekanli, A., Xu, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101823 · Cited by 861
Self-citationNCBI Reference Sequences: current status, policy and new initiatives
Pruitt, K. D., Tatusova, T., Klimke, W., & Maglott, D. R. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn721 · Cited by 736 · cited 1×
“For each gene, we defined the promoter region as the 1000 bases upstream of the start of the longest gene transcript, as annotated in the RefSeq database(Pruitt et al., 2009).”
BackgroundThe Signaling Adaptor p62 Is an Important NF-κB Mediator in Tumorigenesis
Duran, A., Linares, J. F., Galvez, A. S., Wikenheiser, K., Flores, J. M., Diaz-Meco, M. T., & Moscat, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.001 · Cited by 541 · cited 6×
“p62 is essential in certain solid tumors (Duran et al., 2008; Ling et al., 2012); therefore, we investigated whether p62 serves a”
BackgroundInfluentialLing, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.-F., Chang, Z., Li, J., Peng, B., Fleming, J. B., Wang, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.006 · Cited by 513
Zambelli, F., Pesole, G., & Pavesi, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp464 · Cited by 402 · cited 2×
“We compiled a dataset containing 1867 DNA binding motifs representing the binding preferences of 623 human TFs to search for enriched TF binding sites in the promoter regions of the 5q overexpressed genes(Zambelli et al., 2009).”
MethodNF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies
Zhao, J. L., Rao, D. S., Boldin, M. P., Taganov, K. D., O'Connell, R. M., & Baltimore, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105398108 · Cited by 386
Self-citationPassenger deletions generate therapeutic vulnerabilities in cancer
Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339 · cited 2×
“Chromosome deletions that target tumor suppressor genes also involve multiple neighboring genes, such as with del(5q), and loss of certain neighboring genes may expose cancer-specific vulnerabilities and potential therapeutic targets(Muller et al., 2012; Nijhawan et al., 2012).”
Background
Cited by
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
Heavican, T. B., Bouska, A., Yu, J., Lone, W., Amador, C., Gong, Q., Zhang, W., Li, Y., Dave, B. J., Nairismägi, M.-L., et al. (2019) · Blood · doi:10.1182/blood-2018-09-872549 · Cited by 275
Antonucci, L., Fagman, J. B., Kim, J. Y., Todoric, J., Gukovsky, I., Mackey, M., Ellisman, M. H., & Karin, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519384112 · Cited by 257
Chronic immune response dysregulation in MDS pathogenesis
Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226
Self-citationSynthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
Lee, S. C.-W., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.003 · Cited by 219
“…receptor and IL-1 receptor signaling with downstream activation of MAPK and NF-kB pathways is widely reported in MDS, but the mechanistic basis for this activation have mostly been restricted to MDS with deletion of chromosome 5q (Fang et al., 2014, 2017; Starczynowski, 2014; Varney et al., 2015).”
BackgroundMicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts
Wallace, J. A., & O’Connell, R. M. (2017) · Blood · doi:10.1182/blood-2016-10-697698 · Cited by 203
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
“A gene overexpressed from the intact 5q allele, SQSTM1/p62, that binds and activates TRAF6 is essential for miR-146a–deficient human and mouse HSPCs (Fang et al., 2014).”
BackgroundSelf-citationMuto, T., Walker, C. S., Choi, K., Hueneman, K., Smith, M. A., Gul, Z., Garcia-Manero, G., Ma, A., Zheng, Y., & Starczynowski, D. T. (2020) · Nature Immunology · doi:10.1038/s41590-020-0663-z · Cited by 155
Self-citationNeaga, A., Bagacean, C., Tempescul, A., Jimbu, L., Mesaros, O., Blag, C., Tomuleasa, C., Bocsan, C., Gaman, M., & Zdrenghea, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582915 · Cited by 30
Metadata
- Authors
- Fang, J., Barker, B., Bolanos, L., Liu, X., Jerez, A., Makishima, H., Christie, S., Chen, X., Rao, D. S., Grimes, H. L., Komurov, K., Weirauch, M. T., Cancelas, J. A., Maciejewski, J. P., & Starczynowski, D. T.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 8
- Issue
- 5
- Pages
- 1328-1338
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2101370448
- Cited by
- 66
- References
- 11
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.